You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.
The real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples.
The kits cover the primary genetic targets currently used for assessing the compatibility of hematopoietic cell donors with recipients.
Company highlights during the first half of 2017 include China approval for Novaprep for non-gynecological cancer testing, and a €3 million private financing round.
Through the deal, the companies aim to bring new next-generation sequencing-based oncology diagnostic kits to the Chinese market.
The new BGISEQ-50, a smaller version of the BGISEQ-500, will have research and clinical applications, and BGI plans to register it with the CFDA, too.
China-based Burning Rock will develop cancer diagnostics for Chinese patients based on the Agilent SureSelect target enrichment system.
The diagnostic, a real-time PCR kit for breast cancer stratification, is being reviewed under a special process for the approval of innovative products.
Only about 5 to 6 percent of women in China, mostly in urban areas, currently obtain NIPT, but their number is expected to increase quickly in coming years.
Nebula Genomics will be auctioning George Church's genome as a nonfungible token, according to The Scientist.
Anthony Gregg, the outgoing president of the American College of Medical Genetics and Genomics, has resigned after using racially insensitive language.
Facebook has developed an artificial intelligence approach to predict how drugs interact in cells, New Scientist reports.
In PNAS this week: adaptations among high-altitude Mycobacterium tuberculosis, response of multiple myeloma cells to chemotherapy-induced stress, and more.